立他司特（Lifitegrast）是一種新的細胞間黏附因子的抑制劑，可以通過阻斷細胞間黏附分子-1和整合素蛋白淋巴細胞功能相關抗原-1之間的結合起效。2016年7月，美國食品藥品管理局（FDA）正式批準了5%立他司特滴眼劑（商品名Xiidra^TM）的申請。該藥的臨床試驗主要包括針對干眼癥患者的1個為期12周的II期臨床試驗和3個為期12周的III期臨床試驗，研究結果充分證明了該藥的有效性和安全性。立他司特是FDA批準的第一個可以改善和治療干眼癥癥狀的新藥，其他類似藥物只有環(huán)孢素，在不久的將來其臨床應用會更加廣泛。

Lifitegrast is a novel inhibitor of integrin, which can take effect by blocking the binding of intercellular adhesion molecule 1 and integrin lymphocyte function associated antigen 1. In July 2016, the U.S. Food and Drug Administration (FDA) officially approved the application of lifitegrast ophthalmic solution 5% (commodity name Xiidra^TM). Clinical trials of the drug include a 12-week phase II clinical trial and three 12-week phase III clinical trials for dry eye disease patients. The results of clinical trials have demonstrated the efficacy and safety of the drug. Lifitegrast is the first FDA approved drug to improve and treat dry eye symptoms, and other similar drug is only cyclosporine. It is believed that in the near future clinical application of lifitegrast will be more extensive.